On August 26, 2021 Herantis Pharma Plc ("Herantis"), focusing on disease modifying therapies for debilitating neurodegenerative diseases, reported its half yearly financial report for the period January 1 – June 30, 2021 (Press release, Herantis Pharma, AUG 26, 2021, View Source;results-for-the-first-half-year-january-1—june-30–2021,c3403498 [SID1234586902]). It is available on Herantis’ website (Financial information). Investors, analysts and media are invited to a webcasted live call today at 10:30 EEST / 9:30 CEST.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
To register for Herantis’ 1H 2021 Financial Report live call
Register Here: Herantis’ 1H 2021 Financial Report Live Call
Webinar ID: 235-655-763
Questions can be submitted throughout the webcast event.
Following the webcast of the live call, a recording will be available on Herantis Pharma’s website (www.herantis.com).
Herantis transformed into a pure play CNS biotech company –
Highlights January – June 2021:
Strategic data drive decision taken to fully focus all company resources on Herantis’ CDNF and xCDNF assets, thus becoming a pure play CNS (central nervous system) biotech company.
Selected HER-096 as the xCDNF candidate to take forward into further development for the treatment of Parkinson’s Disease (PD) and other neurodegenerative diseases, an important milestone for the company. HER-096 was selected based on clear and compelling preclinical data including that it:
Effectively penetrates the Blood-Brain-Barrier (BBB)
Potently protects neurons and restores their functional phenotype
Significantly reduces aggregation of the toxic protein alpha-synuclein and the associated neuroinflammation
Restores proteostasis
A study showing CDNF’s therapeutic effects in alpha-synuclein-based animal models was published in Molecular Therapy, a leading scientific journal. This study provides new insight in how CDNF affects alpha-synuclein pathology on the molecular and cellular level.
Entered into an agreement with Nanoform Finland Plc. The collaboration provides for formulation proof-of- concept studies to combine Herantis’ CDNF therapy for Parkinson’s disease, with Nanoform nanoparticle technology.
Two presentations summarizing the results from the Phase I-II First-In-Man Clinical Trial of CDNF in PD were presented at the 15th International Conference on Alzheimer’s and Parkinson’s Diseases, AD/PD 2021.
The clinical trial results from Phase II study investigating Herantis’ patented gene therapy Lymfactin, for the treatment of Breast Cancer Related Lymphedema (BCRL), were inconclusive. The primary purpose of the trial was to determine whether there was an additional benefit of Lymfactin treatment in combination with lymph node transfer surgery, compared to surgery alone. While both treatment groups experienced clear clinical benefits, the trial did not establish additional treatment benefit for Lymfactin in combination with surgery, compared to surgery alone. Strategic decision taken to seek out-licensing partners for the Lymfactin program.
Hilde Furberg was elected to the Board of Directors
Hilde brings 35+ years of global leadership experience both as a Board member and through her years in global sales, marketing, strategy and management in the international Pharma/Biotech industries
Former European Head of Rare Disease Europe/GM and Senior VP Rare Diseases EMEA at Genzyme/Sanofi Genzyme
Successful R&D investor day held in June. Link to the event: Herantis’ Virtual R&D Investor Day 2021
Presented novel evidence of biological and biomarker impact in humans from the CDNF Phase 1 clinical study
Summary and outlook for 2021:
The new Herantis is a pure play CNS company, and the programs are fully focused on disease modifying therapeutics to address the unmet need in Parkinson’s disease and other neurological illnesses. During the remainder of 2021 we will continue executing our roadmap as we aim to complete formulation activities for the new CDNF administrations routes, and continue strengthening the preclinical proof of concept data for HER-096 (xCDNF).